Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR228810 dose-escalation study in mild to moderate Alzheimer's disease
NL-OMON38433Active, not recruiting
- Sponsor
- Sanofi
- Start
- May 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of SAR228810 in Alzheimer's disease (AD) (8 arms), sponsored by Sanofi. Primary endpoints: Safety and tolerability, Pharmacokinetics in plasma and CSF and 13 more. Started May 2013; status: active, not recruiting.
02
Drugs
SAR228810
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON38433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38433.